Study on the real world and biological evidence of Xiaozheng Sanjie method in the treatment of chronic kidney disease based on traditional Chinese medicine flaccidity theory

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2100005474

Enrollment

Unknown

Registered

2021-12-30

Start date

2022-01-01

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Interventions

control group:Traditional Chinese medicine compound

Control group:Conventional treatment

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: ? Stage 3-4 patients who meet the diagnostic criteria specified in the 2012 KDIGO clinical practice guidelines for chronic kidney disease (CKD) (kidney international supplies. 2013,3:1-150.) ? Age 18-75 years old. ? The patient or his guardian has signed the informed consent before participating in the screening.

Exclusion criteria

Exclusion criteria: ? Acute renal injury caused by various causes. ? Patients with severe primary diseases such as liver and hematopoietic system, serious infection, mental abnormalities and malignant tumors. ? Patients with renal replacement therapy such as hemodialysis, peritoneal dialysis and kidney transplantation. ? Pregnant or lactating women under the age of 18 or over 75. ? Other clinical trials are under way.

Design outcomes

Primary

Measure	Time frame
Renal function index;	—

Countries

China

Contacts

Public ContactJunmingfan

junmingfan@163.com13908199530

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026